Renal Insufficiency, Acute Clinical Trial
— INFERNALOfficial title:
Renal Function Evaluation in an Ultra Endurance Race: On the Interest of Monitoring Specific Biomarkers to Asses Renal Risk.
Verified date | April 2017 |
Source | Central Hospital, Nancy, France |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
During ultra endurance events, athletes experience extreme physical and mental demands,
sometimes at the limits of the adaptive response to human physiology. This is particularly
true for the renal function, and some evidence for acute renal failure has already been
shown, sometimes leading to dialysis. However, the precise mechanisms involved in acute renal
failure in such ultra endurance races are not clearly elucidated.
The aim of our study is to estimate glomerular filtration rate from serum and urinary
creatinine and cystitin C at the beginning and at the end of a 110 km ultra endurance race.
Our hypothesis is that during the ultra endurance race, renal function may be injured, with a
risk for the athlete.
Status | Completed |
Enrollment | 54 |
Est. completion date | September 10, 2017 |
Est. primary completion date | September 10, 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Age: At least 20 years old - Athlete that is officially registered to the 110 km race (INFERNAL Trail des Vosges) - Athlete informed by a member (MD) of the Medical Staff of the race. - Athlete that gives and signes the informed consent to the research protocol Exclusion Criteria: - Athlete with a known disease that needs the following medications: - Medications influencing the renin-angiotensin-aldosteron system (angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, aldosteron receptor blockers) - Diuretic drugs - Anticoagulant drugs - Non-steroidal anti-inflammatory drugs - Athlete with a known thyroid disease (because of the influence on the serum cystatin level) - Athlete with a know renal disease - Athlete with a know inflammatory disease |
Country | Name | City | State |
---|---|---|---|
France | Stade des Perrey | Saint Nabord | Lorraine |
Lead Sponsor | Collaborator |
---|---|
Central Hospital, Nancy, France |
France,
Didier S, Vauthier JC, Gambier N, Renaud P, Chenuel B, Poussel M. Substance use and misuse in a mountain ultramarathon: new insight into ultrarunners population? Res Sports Med. 2017 Apr-Jun;25(2):244-251. doi: 10.1080/15438627.2017.1282356. Epub 2017 Jan 23. — View Citation
Hoffman MD, Stuempfle KJ, Fogard K, Hew-Butler T, Winger J, Weiss RH. Urine dipstick analysis for identification of runners susceptible to acute kidney injury following an ultramarathon. J Sports Sci. 2013;31(1):20-31. doi: 10.1080/02640414.2012.720705. Epub 2012 Oct 4. — View Citation
Hoffman MD, Weiss RH. Does Acute Kidney Injury From an Ultramarathon Increase the Risk for Greater Subsequent Injury? Clin J Sport Med. 2016 Sep;26(5):417-22. doi: 10.1097/JSM.0000000000000277. — View Citation
Poussel M, Vauthier JC, Renaud P, Gambier N, Chenuel B, Ladrière M. [Acute kidney injury following naproxene use in an ultraendurance female athlete]. Presse Med. 2013 Sep;42(9 Pt 1):1274-6. doi: 10.1016/j.lpm.2012.09.030. Epub 2013 Feb 27. French. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Glomerular filtration rate | The glomerular filtration rate will be calculated from the serum and urinary creatinine and cystatin C dosage | 30 minutes at baseline (09.07.2017), and 30 minutes at the end of the 110 km race (2 or 3 days after baseline) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04605705 -
NIRS for the Diagnosis and Prevention of Acute Renal Failure
|
||
Completed |
NCT02531724 -
Effects of Levosimendan in Acute Kidney Injury After Cardiac Surgery
|
Phase 4 | |
Recruiting |
NCT04334707 -
Kidney Precision Medicine Project
|
||
Completed |
NCT03311256 -
Determination of the "Tissue Transit Time" (TTT)
|
||
Terminated |
NCT02808052 -
Evaluate Safety and Pharmacokinetics of Minocin (Minocycline) for Injection in Subjects With Renal Insufficiency
|
Phase 1 | |
Recruiting |
NCT03489759 -
The Effect of Vitamin E-coated Polysulfone Membrane on Oxidative Stress, Inflammation and Monocytes in Critically Ill Patients in CRRT
|
N/A | |
Active, not recruiting |
NCT05384899 -
Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol
|
||
Recruiting |
NCT05240833 -
VExUS-guided Fluid Management in Patients With Acute Kidney Injury in the Intensive Care Unit
|
N/A | |
Withdrawn |
NCT00855127 -
New Urine and Blood Markers for Acute Kidney Injury in Liver Transplant Patients
|
N/A | |
Suspended |
NCT00190034 -
Acetylcysteine Against Acute Renal Insult During Cardiopulmonary Bypass.
|
Phase 4 | |
Completed |
NCT01233882 -
Bosutinib In Subjects With Renal Impairment
|
Phase 1 | |
Active, not recruiting |
NCT00806039 -
Impact of Early Renal Involvement on the Development of Severe In-hospital Renal Failure
|
N/A | |
Terminated |
NCT00322933 -
Intermittent Versus Continuous Renal Replacement Therapy for Acute Renal Failure
|
N/A |